MedPath

MSI Methylation Sciences Inc

🇨🇦Canada
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine

Phase 1
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2020-11-10
Last Posted Date
2020-11-10
Lead Sponsor
MSI Methylation Sciences, Inc.
Target Recruit Count
34
Registration Number
NCT04623034

Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)

Phase 2
Completed
Conditions
Major Depressive Disorder (MDD)
Interventions
Drug: Placebo
First Posted Date
2013-07-31
Last Posted Date
2016-03-18
Lead Sponsor
MSI Methylation Sciences, Inc.
Target Recruit Count
376
Registration Number
NCT01912196
Locations
🇺🇸

MSI Investigational Site, Bellevue, Washington, United States

🇺🇸

MSI INvestigational Site, Kissimmee, Florida, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath